abhd6

KT182 is a selective and  potent inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells.

KT203, a selective and potent structural domain 6 (ABHD6) inhibitor of alpha/beta hydrolytic enzymes, exhibits potential antiviral and anti-inflammatory properties for pneumonia research.

JZP-430 is an effective, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) (IC50: 44 nM). It also shows ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL).

KT185 is an orally bioavailable, highly selective, blood-brain barrier-permeable small-molecule inhibitor of α/β-hydrolyase domain protein 6 (ABHD6), with an inhibitory concentration (IC₅₀) of 0.21 nM against ABHD6. KT185 effectively inhibits ABHD6-mediated hydrolysis of 2-arachidonylglycerol (2-AG) and is used to study the role of ABHD6 in central nervous system and metabolic signaling pathways.

WWL70 is a selective inhibitor of alpha/beta hydrolase domain 6 with an IC50 of 70 nM.

WWL123 is a potent and selective ABHD6 inhibitor (IC50=430 nM). WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice.

AA38-3 (1-Piperidinecarboxylic acid, 4-nitrophenyl ester) inhibites three SHs (ABHD6, ABHD11, and FAAH)

MAGL-IN-4 (His121 ARG57) is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.

SA57 is a potent, selective inhibitor of FAAH(IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH).

JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.

LEI-106 is an effective dual inhibitor of DAGL-α (sn-1-Diacylglycerol lipase α) and ABHD6 (α/β-hydrolase domain 6), with Ki values of 0.7 and 0.8 μM respectively, suitable for obesity and metabolic syndrome research.

JCP-170 is an ABHD6 inhibitor.

JCP-265 is an ABHD6 inhibitor.

UCM710 is a dual inhibitor of α/β hydrolase domain 6 (ABHD6) and fatty acid amide hydrolase (FAAH).

(R)-KT109 is the (R) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (R)-KT109 is an inhibitor of DAGLβ (IC50 = 0.79 nM) and of DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol . It also inhibits α/β-hydrolase domain-containing protein 6 (ABHD6) with an IC50 value of 2.51 nM. (R)-KT109 is more potent at DAGLβ, DAGLα, and ABHD6 than (S)-KT109 .

JJH260 is an N-hydroxy hydantoin carbamate that inhibits androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs). It blocks the hydrolysis of 9-PAHSA with an IC50 value of 0.57 μM. JJH260 also inhibits the novel FAHFA hydrolase androgen-dependent TFPI-regulating protein (ADTRP; IC50 = 8.5 μM), as well as the serine hydrolase ABHD6 and the lysophospholipases LYPLA1 and LYPLA2. JJH260 inhibits the FAHFA hydrolase activity of LNCaP and T cell lysates and intact cells.

(S)-KT109 is the (S) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (S)-KT109 is a less potent inhibitor of DAGLβ (IC50 = 39.81 nM), DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM), and α/β-hydrolase domain-containing protein 6 (ABHD6; IC50 = 630.9 nM) than (R)-KT109 .

ABC34 is an inactive control probe for JJH260 , the inhibitor of androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs). ABC34 demonstrates an IC50 value greater than 25 μM for the inhibition of 9-PAHSA but is more potent in blocking the serine hydrolase ABHD6 and the palmitoyl-protein hydrolase PPT1, which are both off-targets of JJH260.

FP-biotin is a potent organophosphorus toxicant ideal for identifying novel biomarkers of organophosphorus exposure. It measures FAAH, ABHD6, and MAG-lipase activity specifically in plasma studies, thanks to the efficient purification of biotinylated peptides through binding to immobilized avidin beads.

JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 value of 392 nM, and exhibits no inhibitory effects on monoacylglycerol lipase (MAGL), ABHD12, fatty acid amide hydrolase (FAAH), or other serine hydrolases. JZP-MA-13 also serves as a positron emission tomography (PET) ligand for in vivo imaging of ABHD6.

JZP-MA-11 is a positron emission tomography (PET) ligand that specifically targets the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. It exhibits selective inhibition of ABHD6 with an IC50 value of 126 nM and can cross the blood-brain barrier (BBB). The compound, labeled with [18F], shows promising potential for preclinical evaluation in mice and nonhuman primates (NHP) as a tool for investigating brain ABHD6 activity [1].

JW 618 is a selective inhibitor of ABHD6, demonstrating inhibition concentrations (IC50 values) of 38 nM for mouse ABHD6 and 13 nM for rat ABHD6, indicating its potent activity across species [1].

WWL229 is a selective inhibitor of Ces3, acting by inhibiting recombinant Ces3 while not affecting Ces1f, ABHD6, or other tested serine hydrolases, and replicating the effects of WWL113 in adipocytes.